Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children

Report of 2 cases

Richard C. E. Anderson, M.D., 1 Benjamin Kennedy, M.D., 1 Candix L. Yanes, R.N., 1 James Garvin, M.D., Ph.D., 2 Michael Needle, M.D., 2 Peter Canoll, M.D., Ph.D., 3 Neil A. Feldstein, M.D., 1 and Jeffrey N. Bruce, M.D. 1

Departments of 1 Neurosurgery, 2 Oncology, and 3 Pathology and Cell Biology, Columbia University, College of Physicians and Surgeons, New York, New York

Convection-enhanced delivery (CED) for the treatment of malignant gliomas is a technique that can deliver chemotherapeutic agents directly into the tumor and the surrounding interstitium through sustained, low-grade positive-pressure infusion. This allows for high local concentrations of drug within the tumor while minimizing systemic levels that often lead to dose-limiting toxicity. Diffuse intrinsic pontine gliomas (DIPGs) are universally fatal childhood tumors for which there is currently no effective treatment. In this report the authors describe CED of the topoisomerase inhibitor topotecan for the treatment of DIPG in 2 children.

As part of a pilot feasibility study, the authors treated 2 pediatric patients with DIPG. Stereotactic biopsy with frozen section confirmation of glial tumor was followed by placement of bilateral catheters for CED of topotecan during the same procedure. The first patient underwent CED 210 days after initial diagnosis, after radiation therapy and at the time of tumor recurrence, with a total dose of 0.403 mg in 6.04 ml over 100 hours. Her Karnofsky Performance Status (KPS) score was 60 before CED and 50 posttreatment. Serial MRI initially demonstrated a modest reduction in tumor size and edema, but the tumor progressed and the patient died 49 days after treatment. The second patient was treated 24 days after the initial diagnosis prior to radiation with a total dose of 0.284 mg in 5.30 ml over 100 hours. Her KPS score was 70 before CED and 50 posttreatment. Serial MRI similarly demonstrated an initial modest reduction in tumor size. The patient subsequently underwent fractionated radiation therapy, but the tumor progressed and she died 120 days after treatment.

Topotecan delivered by prolonged CED into the brainstem in children with DIPG is technically feasible. In both patients, high infusion rates (> 0.12 ml/hr) and high infusion volumes (> 2.8 ml) resulted in new neurological deficits and reduction in the KPS score, but lower infusion rates (< 0.04 ml/hr) were well tolerated. While serial MRI showed moderate treatment effect, CED did not prolong survival in these 2 patients. More studies are needed to improve patient selection and determine the optimal flow rates for CED of chemotherapeutic agents into DIPG to maximize safety and efficacy. Clinical trial registration no.: NCT00324844. (http://thejns.org/doi/abs/10.3171/2012.10.PEDS12142)

Key Words • convection-enhanced delivery • topotecan • pediatric neurosurgery • brainstem tumor • pontine glioma • oncology
stem tumors from intrathecal administration relies on diffusion, which severely constrains tissue distribution and produces heterogeneous dispersion. Convection-enhanced delivery is a strategy developed by Oldfield and colleagues to deliver agents directly into tumors and surrounding brain through the interstitial space. Stereotactically placed catheters connected to pumps provide a continuous low positive-pressure microinfusion that distributes chemotherapeutic agents by bulk flow, providing high local concentrations of drugs in the tumor while avoiding systemic toxicity. Extensive mathematical and experimental models have demonstrated the advantages of bulk flow over simple diffusion methods, including systemic chemotherapy and intrathecal administration.

Clinical evidence in support of CED with topotecan recently became available as a Phase Ib clinical trial safely demonstrated regression of recurrent supratentorial malignant gliomas in adults using CED. In this report, we discuss the technique and outcomes after topotecan administration via CED into the brainstem of 2 pediatric patients with DIPGs.

Case Reports

Methods

Patient Selection and Study Design. Both patients were treated at the Morgan Stanley Children's Hospital and Columbia University Medical Center under the auspices of an Institutional Review Board study after an investigational new drug application was approved and informed consent was obtained. Eligibility criteria included: 1) clinical and radiological evidence of a DIPG, 2) a KPS score of at least 60, and 3) age less than 18 years. Tumors with large cysts or extreme expansion of the pons on initial MRI were excluded for CED. Study patients were treated as part of a larger prospective Phase Ib open-label, nonrandomized, dose escalation study of adult patients with recurrent supratentorial malignant glioma (clinical trial registration no. NCT00324844). The study was designed for patients to receive an infusion of topotecan via CED at 0.0667 mg/ml, which was the midlevel dose of the adult dose escalation study and one-third the concentration that at 0.0667 mg/ml, which was the midlevel dose of the adult dose escalation study and one-third the concentration that dosed 54 Gy) with improvements in her gait and swallowing. Approximately 4 months later, she developed worsening gait and speech. Physical examination demonstrated bilateral CN VI palsy, diffuse hyperreflexia, and ataxic gait. A CT scan and MRI showed a diffusely enlarged pons, consistent with DIPG (Fig. 2A and B).

She underwent 6 weeks of radiation therapy (total dose 54 Gy) with improvements in her gait and swallowing. Approximately 4 months later, she developed worsening gait and speech. Physical examination again demonstrated gait ataxia, dysarthria, CN VI palsy, and increased tone bilaterally. Magnetic resonance imaging showed increased tumor size with new areas of enhancement as well as new-onset hydrocephalus (Fig. 2C). She underwent an uncomplicated endoscopic third ventriculostomy resulting in some improvement of her gait, but no change in her speech or CN VI palsy. Several days later, with a baseline KPS score of 60, the patient and family elected to proceed with CED.
The patient underwent a frame-based stereotactic biopsy to confirm glioma followed by placement of bilateral catheters as previously described (Fig. 2D). Surgery was uncomplicated and the patient was transported to the pediatric ICU intubated. Infusion of topotecan via CED was started at a rate of 0.08 ml/hr and a concentration of 0.0667 mg/ml per catheter. After 17 hours of infusion (total volume 2.72 ml), she developed increased spasticity and decreased movement of all 4 extremities. The infusion was stopped, her dexamethasone dose was increased, and an MRI study was performed. The MR images showed no change. Her strength improved over the next 48 hours, and by postoperative Day 4 she was nearly back to her neurological baseline but with persistent spasticity. The infusion was restarted at a lower rate of 0.02 ml/hr at the same concentration (0.0667 mg/ml) and continued for another 83 hours until completion. Her examination findings remained stable through the end of the treatment, the catheters were removed, and she was extubated uneventfully. She received a total of 0.403 mg of topotecan in a total volume of 6.04 ml. Posttreatment MRI demonstrated evidence of drug infusion into the tumor, but no changes in the overall tumor size (Fig. 2E and F). Her spasticity remained after cessation of topotecan therapy, and treatment with baclofen was initiated. Her KPS score 3 days after treatment was 50. Her final pathological diagnosis was diffuse infiltrating glioma. Over the next 2 months, her level of consciousness and speech gradually declined. An MRI study performed 1 month after CED demonstrated significant tumor growth (Fig. 2G and H) and she eventually died 49 days after CED. The parents agreed to organ donation and no autopsy was performed.

Case 2. This young girl was brought to the emergency department at the age of 5 years 10 months with a...
2-month history of progressive right leg and arm weakness, right facial weakness, double vision, slurred speech, difficulty with ambulation, and falls. Her main neurological findings included right CN VI and XII palsies, right hemiparesis, and a slow, unbalanced gait that required assistance. She had 3+ bilateral patellar reflexes, 4+ Achilles reflexes, and upgoing toes. Her KPS score at this point was 70. An MRI study revealed diffuse expansion of the pons with T2 signal hyperintensity (Fig. 3A) and patchy heterogeneous enhancement with contrast agent administration (Fig. 3B), consistent with DIPG. She had no hydrocephalus. Dexamethasone therapy was initiated with little improvement. Three weeks later, she was admitted to the Morgan Stanley Children's Hospital of New York at the Columbia University Medical Center, where a percutaneous endoscopic gastrostomy tube was placed due to swallowing dysfunction. After a brief recovery she elected for CED as previously described.

Histological analysis of the biopsy showed a moderately cellular glial neoplasm with prominent nuclear atypia and rare mitotic figures, consistent with anaplastic astrocytoma (WHO Grade III). Two catheters were placed stereotactically with the tips positioned approximately a centimeter apart in the diffusely enlarged pons, and placement was confirmed with an immediate postoperative MRI (Fig. 3C). The patient was extubated and transferred to the pediatric ICU. Infusion of topotecan via CED was begun at a concentration of 0.0667 mg/ml and a rate of 0.06 ml/hr through each catheter. After 24 hours of infusion, she became more hypophonic with reduced movement of her lower extremities. Her dexamethasone dose was increased and the infusion was stopped.

On postoperative Days 2 and 3, she continued to have lower-extremity weakness and hypophonia and also developed right arm weakness. On postoperative Day 4, an MRI study showed evidence of drug infusion within the tumor with no new hemorrhage or infarction (Fig. 3D). Her neurological examination findings subsequently improved, with increasing strength, and on postoperative Day 5 the infusion was restarted at the same lower rate of 0.02 ml/hr from each catheter, but with half the concentration (at 0.0334 mg/ml). Before the infusion was restarted, she had some mild transient episodes of tachypnea but without oxygen desaturation and was electively intubated to protect her airway. The infusion was continued for another 69 hours with no further changes in her neurological examination findings. She received a total of 0.284 mg of topotecan in a total volume of 5.30 ml.

After a posttreatment MRI demonstrated a larger volume of distribution of topotecan (Fig. 3E), both catheters were removed and she was extubated uneventfully. Her KPS score 3 days after treatment was 50. Her neurological examination findings improved over the next several days in the hospital and during a 10-day course in acute rehabilitation. The final pathological diagnosis was anaplastic astrocytoma (WHO Grade III). Approximately 1 month following treatment, an MRI study showed further enhancement but a slight decrease in overall size of the tumor (Fig. 3F). She then began a 6-week course of fractionated radiation therapy at a dose of 54 Gy. Her examination findings continued to improve during radiation treatment, but she continued to show lower-extremity weakness.
Convection-enhanced delivery is a method of regional drug delivery pioneered by Oldfield et al. with demonstrated safety in several clinical trials of adult patients. Bulk flow provides a relatively uniform distribution of drug within the treatment volume with a steep drop in drug concentrations outside the volume of distribution, beyond which further distribution ultimately occurs by diffusion. Preclinical studies from our laboratory and others have demonstrated that CED in rat and nonhuman primate glioma models can achieve widespread perfusion of drugs throughout the brain and brainstem. For locally invasive and nonresectable tumors like DIPG, this treatment provides elevated concentrations of drug in the peritumoral region with undetectable serum drug concentrations, thereby avoiding systemic toxicity such as myelosuppression. Our previous studies showed that the blood-brain barrier to natural product drugs like topotecan was still partially intact in gliomas but not intact in metastatic brain lesions and therefore, while this partially functioning blood-brain barrier could impede the transit of systemically delivered topotecan into brain tumors, it is not an impediment with CED.

Topotecan, a topoisomerase I inhibitor, is an ideal chemotherapeutic agent for CED to malignant gliomas for several reasons: 1) it is cytotoxic to glioma cells and nontoxic to normal brain at clinical doses; 2) topoisomerase I levels are higher in glioma cells and tumor tissue than normal brain; and 3) it is a natural product drug with a high molecular weight and thus should only minimally traverse the blood-brain barrier from the brain to the systemic circulation. While previous clinical trials have shown minimal effects when topotecan is delivered intravenously, we have previously shown that CED of topotecan had significant antitumor effects and led to prolonged survival in animal models. Furthermore, we have recently completed a Phase Ib dose escalation study of topotecan via CED in patients with recurrent supratentorial malignant glioma that demonstrated significant antitumor activity with prolonged survival and minimal drug-associated toxicity.

Treatment by means of CED has been previously reported in 2 children, one of whom had a DIPG. Lonser and colleagues reported CED of the antiglioma cytotoxin IL-13PE directly into the brainstem of a 4-year-old girl with a recurrent DIPG. Infusion was performed through a transfrontal approach at increasing flow rates (0.03–0.3 ml/hr) until a total infusion volume of 1.4 ml was reached. The patient developed mild lethargy and exacerbation of her preoperative bilateral CN VI palsy that resolved within 5 days of steroid treatment. Magnetic resonance imaging demonstrated tumor stability at 4 weeks posttreatment but recurrence at 2 months, and the child ultimately died 4 months posttreatment. In another study, Saito and colleagues reported CED of nimustine hydrochloride for treatment of a cerebellar glioblastoma that was resected but recurred with partial extension into the brainstem. Infusion of nimustine hydrochloride at 0.25 mg/ml was performed through a transfrontal approach at increasing flow rates (0.06–0.3 ml/hr) until a total volume of 7.02 ml was achieved after 60 hours. The patient developed diplopia and a hemiparesis that resolved within 1 week. Posttreatment MRI demonstrated good distribution of drug within the brainstem, showing widespread perfusion of drug.

**Discussion**

We have demonstrated for the first time that CED of topotecan into the brainstem of children with DIPG is technically feasible. In this limited study, we have also shown that a total volume of infusion greater than 2.7 ml with flow rates greater than 0.12 ml/hr led to new neurological deficits, prompting the need for further studies to determine optimal flow rates, drug concentration, and patient selection.
tion of the drug throughout the tumor and reduction in the enhancing portion of the tumor. The patient remained clinically well until his tumor recurred, and he died 6 months posttreatment.

Our study differs from these 2 prior studies in several important ways. The most significant difference is the higher complication rate seen in our study. There are several possible reasons for this; most notably, the total volumes of infusion were significantly higher in our patients than in the report of Lonser et al.\textsuperscript{17} (5.30 ml and 6.04 ml vs 1.4 ml total volume). In both of our patients, symptoms did not occur during CED until after a total volume of more than 2.7 ml was infused. It is also possible that the complications seen in our patients were due to higher initial flow rates than previously used (> 0.12 ml/hr vs 0.03 ml/hr). Although much higher flow rates and volumes of infusion have been well tolerated in supratentorial CED studies, we hypothesize that the reduced extracellular space intrinsic to the brainstem in the setting of a DIPG is likely to limit the tolerated total volume and flow rate of infusate. In the study by Saito et al.,\textsuperscript{27} a total volume of 7.02 ml was reached, with flow rates up to 0.3 ml/hr. However, it seems likely that these higher volumes and flow rates were achievable because the child did not have a DIPG. Rather, CED was performed for tumor recurrence in the lateral brainstem in the setting of a large resection cavity that could accommodate larger volumes and flow rates.

Our study also differs from previous studies in that our length of infusion was much longer (100 hours vs 4.6 hours\textsuperscript{10} and 60 hours\textsuperscript{17}). This is less likely to be problematic because the complications seen in our patients occurred within the first 24 hours, with clinical improvement or stabilization after flow rates were reduced. Furthermore, preclinical studies have shown safety with prolonged infusions up to 7 days in rat brainstem models.\textsuperscript{21}

Other differences include the number and trajectory of implanted catheters for CED. We chose to implant 2 catheters rather than a single catheter to try to maximize the volume of drug distribution throughout the tumor. In addition, we chose a posterior fossa approach with 1 catheter down each cerebellar peduncle rather than a transfrontal approach in order to minimize the amount of normal brain tissue traversed with the catheter. It is possible that some of the morbidity seen in our patients was due to the biopsy itself or the use of bilateral catheters rather than a single catheter. However, it is unlikely that these differences contributed to the complications in these patients, as there did not appear to be any morbidity associated with the initial biopsy or implanting of the catheters.

Finally, complications could have been related to the concentration of topotecan initially used (0.0667 mg/ml), although this seems less likely since both preclinical and adult human studies have established safety with higher concentrations of topotecan (0.1 mg/ml).

There are limitations to this study. First, detailed information regarding drug distribution throughout the brainstem cannot be determined because a tracer was not used.\textsuperscript{10,17,23} Recent studies using tracers with CED in nonhuman primates have demonstrated that the volume of distribution achieved with CED is approximately twice the volume seen on traditional T2-weighted MR images.\textsuperscript{11}

In our patients, the T2 signal changes on MRI were asymmetrical and inconsistent. Although the reasons for this are not known, different tissue densities or anatomical locations of the catheter tips within the tumors may in part explain these differences. Second, prior to this trial, we did not have any clinical evidence that topotecan delivered via CED was effective against malignant gliomas. We chose to use topotecan, because in our preclinical laboratory studies, topotecan had a reasonable safety profile and was most effective against malignant gliomas.\textsuperscript{12} Furthermore, by targeting proliferative processes such as DNA repair, synthesis, and cell proliferation, topotecan provides a more clinically specific and effective mechanism of action than prior studies using CED with targeted toxins for supratentorial malignant gliomas.\textsuperscript{14,16,26,28}

Although the clinical outcomes for these 2 patients were disappointing, the need for Phase I clinical trials with routine histological sampling along with CED of therapeutic agents in children with DIPG is warranted given the lack of treatment alternatives.\textsuperscript{13} These 2 patients were treated as part of a Phase Ib trial designed specifically to determine feasibility, not efficacy. Additional Phase I studies of CED utilizing dose escalation with lower infusion volumes and flow rates in combination with tracer are needed to determine optimal safety and efficacy to treat children with DIPG.

Disclosure

This study was supported by NIH grant 5R01CA89395. This publication was made possible by grant number UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the NIH, and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at the NCRR website. Information on Re-engineering the Clinical Research Enterprise can be obtained from the NIH Roadmap website.

Author contributions to the study and manuscript preparation include the following. Conception and design: Anderson, Garvin, Needle, Canoll, Feldstein, Bruce. Acquisition of data: Anderson, Yanes, Garvin, Needle, Canoll, Feldstein, Bruce. Analysis and interpretation of data: Anderson, Kennedy, Garvin, Needle, Canoll, Feldstein, Bruce. Drafting the article: Anderson, Kennedy, Canoll, Feldstein, Bruce. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors.

Acknowledgment

The authors would like to thank Nancy Heim for her original artwork.

References

Convection-enhanced delivery of topotecan for DIPG


